A Growing Threat Inside Hospitals
Drug resistant bacterial infections are emerging as a major challenge for India’s healthcare system, with new research showing that they can lead to higher mortality, longer hospital stays and substantially greater treatment costs than infections caused by drug sensitive bacteria.
An ICMR study involving 20 tertiary care hospitals analysed 1.6 lakh hospitalised patients between April 2022 and April 2025. Among them, 26,213 patients had infections caused by four major Gram negative bacteria: E. coli, Klebsiella pneumoniae, Acinetobacter baumannii and Pseudomonas aeruginosa.
Carbapenem Resistance Raises Concern
One of the most worrying findings was that 61.1% of the infections studied were carbapenem resistant.
Carbapenems have traditionally been considered important last line antibiotics for some serious bacterial infections. Increasing resistance to these medicines can leave clinicians with fewer effective treatment options.
The findings reinforce that antimicrobial resistance is not simply a future possibility. It is already creating serious consequences for patients and healthcare systems.
Resistant Infections Are Linked to Higher Mortality
The study compared mortality between patients infected with resistant and susceptible forms of the same bacteria.
For Klebsiella pneumoniae, mortality was 31.2% among patients with resistant infections compared with 23.5% among those with susceptible infections. For E. coli, mortality was 24.4% versus 17.3%.
Similar differences were observed with Acinetobacter baumannii, where mortality was 37.9% for resistant infections compared with 32.8% for susceptible infections, and Pseudomonas aeruginosa, where the figures were 28.9% and 20.2%, respectively.
These differences demonstrate the clinical consequences of losing antibiotic effectiveness.
Treatment Becomes More Expensive
Drug resistance also carries a significant financial burden.
The study found that antibiotic treatment costs were 1.1 to 2 times higher for resistant infections. Average antibiotic treatment costs were approximately $420 for resistant E. coli compared with $211 for susceptible infections.
For other organisms, the average costs were also higher, including $587 versus $505 for Klebsiella pneumoniae, $655 versus $436 for Acinetobacter baumannii and $702 versus $510 for Pseudomonas aeruginosa.
Higher costs can result from the need for alternative antibiotics, combination therapies, additional diagnostics and longer clinical management.
Longer Hospital Stays Add to the Burden
Drug resistant infections can also keep patients in hospitals for longer periods.
Patients with resistant E. coli infections had an average hospital stay of 23.1 days compared with 17.8 days among those with susceptible infections.
Longer hospitalisation increases treatment expenditure and places additional pressure on hospital beds, healthcare professionals and critical care resources.
Faster Diagnostics Could Make a Difference
Identifying the responsible organism and determining its antibiotic resistance pattern can take several days using conventional culture based methods.
Experts noted that molecular diagnostics can potentially accelerate this process, allowing clinicians to understand resistance patterns sooner and make more informed treatment decisions.
This makes timely and accurate diagnostics an important part of the fight against antimicrobial resistance.
The Answer Is Not Simply Stronger Antibiotics
The study’s findings underline an important principle in modern infection management: the solution to antimicrobial resistance cannot simply be the development or use of increasingly powerful antibiotics.
Researchers emphasised the importance of infection prevention, timely diagnostics, responsible antibiotic use, antimicrobial stewardship and stronger surveillance systems.
Preventing an infection from occurring in the first place can be far more effective than trying to treat a resistant infection after it develops.
What Healthcare Institutions Need to Prioritise
Hospitals have a critical role in reducing the spread of antimicrobial resistance. Strong infection prevention protocols, appropriate antibiotic prescribing, laboratory surveillance and rapid identification of resistant organisms can all contribute to better outcomes.
Antimicrobial stewardship programmes can also help ensure that antibiotics are used when clinically appropriate, at the right dose and for the appropriate duration.
Important Context Around the Study
The researchers have cautioned that the study involved tertiary care hospitals, where critically ill and referred patients are more likely to receive treatment.
Therefore, the findings should not be interpreted as a measure of individual hospital performance. Instead, they provide important evidence about the wider clinical and economic consequences associated with drug resistant infections.
